190 related articles for article (PubMed ID: 38226713)
21. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
[TBL] [Abstract][Full Text] [Related]
22. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
23. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis.
Mease PJ; Deodhar AA; van der Heijde D; Behrens F; Kivitz AJ; Neal J; Kim J; Singhal S; Nowak M; Banerjee S
Ann Rheum Dis; 2022 Jun; 81(6):815-822. PubMed ID: 35241426
[TBL] [Abstract][Full Text] [Related]
25. Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial.
Papp KA; Gordon K; Strober B; Zhuo J; Becker B; Zhong Y; Beaumont JL; Pham TP; Kisa R; Napoli AA; Banerjee S; Armstrong AW
JAMA Dermatol; 2024 Feb; 160(2):204-209. PubMed ID: 38117487
[TBL] [Abstract][Full Text] [Related]
26. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
[TBL] [Abstract][Full Text] [Related]
28. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.
Langley RG; Sofen H; Dei-Cas I; Reich K; Sigurgeirsson B; Warren RB; Paul C; Szepietowski JC; Tsai TF; Hampele I; You R; Charef P; Papavassilis C
Br J Dermatol; 2023 Feb; 188(2):198-207. PubMed ID: 36763857
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness and safety of deucravacitinib treatment for moderate-to-severe psoriasis in real-world clinical practice in Japan.
Hagino T; Saeki H; Fujimoto E; Kanda N
J Dermatolog Treat; 2024 Dec; 35(1):2307489. PubMed ID: 38305215
[TBL] [Abstract][Full Text] [Related]
30. Deucravacitinib in the treatment of psoriasis.
Estevinho T; Lé AM; Torres T
J Dermatolog Treat; 2023 Dec; 34(1):2154122. PubMed ID: 36453809
[TBL] [Abstract][Full Text] [Related]
31. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
[TBL] [Abstract][Full Text] [Related]
32. Safety, tolerability, pharmacokinetics and efficacy of HB0017, a humanized monoclonal antibody that targets interleukin-17A, in healthy participants and patients with moderate-to-severe plaque psoriasis.
Jiang C; Du Y; Liu X; Wang J; Ge C; Xu J; Wang S; Li B; Zhu G; Zhang W; Qian Q; Ma C; Zhu X; Zhan Y; Yang Y
Br J Dermatol; 2023 Dec; 190(1):28-36. PubMed ID: 37669307
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
Paller AS; Seyger MMB; Alejandro Magariños G; Bagel J; Pinter A; Cather J; Keller S; Rodriguez Capriles C; Gontijo Lima R; Gallo G; Little CA; Edson-Heredia E; Li L; Xu W; Papp K;
Br J Dermatol; 2020 Aug; 183(2):231-241. PubMed ID: 32316070
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study.
Landis MN; Smith SR; Berstein G; Fetterly G; Ghosh P; Feng G; Pradhan V; Aggarwal S; Banfield C; Peeva E; Vincent MS; Beebe JS; Tarabar S
Br J Dermatol; 2023 Jul; 189(1):33-41. PubMed ID: 36972293
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects.
Jing S; Lin Y; Dockens R; Marchisin D; He B; Girgis IG; Chimalakonda A; Murthy B; Aras U
Dermatol Ther (Heidelb); 2023 Dec; 13(12):3153-3164. PubMed ID: 37981596
[TBL] [Abstract][Full Text] [Related]
36. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
Nakagawa H; Niiro H; Ootaki K;
J Dermatol Sci; 2016 Jan; 81(1):44-52. PubMed ID: 26547109
[TBL] [Abstract][Full Text] [Related]
37. Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse).
Stein Gold LF; Bagel J; Tyring SK; Hong HC; Pavlovsky L; Vender R; Pinter A; Reich A; Drogaris L; Wu T; Patel M; Soliman AM; Photowala H; Stakias V; Richter S; Papp KA
Br J Dermatol; 2023 Oct; 189(5):540-552. PubMed ID: 37488811
[TBL] [Abstract][Full Text] [Related]
38. Clinical Utility of Deucravacitinib for the Management of Moderate to Severe Plaque Psoriasis.
Jin JQ; Spencer RK; Reddy V; Bhutani T; Liao W
Ther Clin Risk Manag; 2023; 19():413-423. PubMed ID: 37223005
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double-blind, placebo-controlled study.
Seo SJ; Shin BS; Lee JH; Jeong H
J Dermatol; 2021 Jun; 48(6):807-817. PubMed ID: 33373480
[TBL] [Abstract][Full Text] [Related]
40. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
